Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab after out-of-hospital cardiac arrest
2018-002686-19Phase 2Completed
- Sponsor
- Department of Cardiology, Rigshospitalet
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiac arrest (SCA) comparing RoActemra with Placebo (2 arms). Primary endpoint: Daily high-sensitivity C-reactive protein over 72 hours. Started Aug 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2018-002686-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002686-19.